ArticleCommunications biology2026
Breaking aromaticity in the anaerobic degradation pathway of phenanthrene comprises only ATP-independent type III aryl-CoA reductases.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The anaerobic degradation pathway of phenanthrene starts with activation through carboxylation to 2-phenanthroic acid, followed by thioesterification to produce 2-phenanthroyl-CoA, which is then reduced to hexahydro-2-phenanthroyl-CoA by two ATP-independent type III aryl-CoA reductases (AprB and AprC) to overcome the resonance energy of the aromatic rings. In this study, we elucidated the reduction of hexahydro-2-phenanthroyl-CoA to octahydro-2-phenanthroyl-CoA and its subsequent reduction to the fully dearomatized diene decahydro-2-phenanthroyl-CoA. The two-electron reduction steps were catalyzed by the heterologously produced and purified hexahydro-2-phenanthroyl-CoA reductase (AprD) and octahydro-2-phenanthroyl-CoA reductase (AprE). AprD and AprE have specific activities of 12.7 and 6.3 nmol min
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.